| abstract |
The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds useful as neurokinin-1 (NK-1) receptor antagonists and inhibitors of tachykinins, particularly substance P. The invention also relates to pharmaceutical formulations comprising these compounds as active ingredients, and the use of the compounds and their formulations in the treatment of certain disorders including vomiting, urinary incontinence, LUTS, depression and anxiety. |